ezetimibe has been researched along with fenofibrate in 56 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (fenofibrate) | Trials (fenofibrate) | Recent Studies (post-2010) (fenofibrate) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 3,058 | 529 | 1,354 |
| Protein | Taxonomy | ezetimibe (IC50) | fenofibrate (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.371 | |
| Adenosine receptor A3 | Homo sapiens (human) | 5.701 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.701 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.118 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.371 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.701 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 8.633 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 1 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (37.50) | 29.6817 |
| 2010's | 32 (57.14) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Császár, A; Márk, L | 1 |
| Cottrell, DA; Falko, JM; Marshall, BJ | 1 |
| Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP | 1 |
| Davies, MJ; Farnier, M; Freeman, MW; Gumbiner, B; Macdonell, G; Mitchel, YB; Perevozskaya, I | 1 |
| Stalenhoef, AF | 1 |
| Borja, J | 1 |
| Giral, P; Jublanc, C; Turpin, G | 1 |
| Bays, HE; Carlson, G; Davies, MJ; Farnier, M; Gumbiner, B; Lo, KW; McKenney, JM; Mitchel, YB; Perevozkaya, I | 1 |
| Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD | 1 |
| Cimadevilla, C; Guillausseau, PJ; Meas, T; Mouly, S; Timsit, J | 1 |
| Chun, P; Chung, S; Moon, YS | 1 |
| Farnier, M | 1 |
| Elisaf, M; Gazi, IF; Kalogirou, M; Kostapanos, M; Saougos, VG; Tambaki, AP; Tselepis, AD; Wolfert, RL | 1 |
| Chrysohoou, C; Singh, S | 1 |
| Elisaf, MS; Florentin, M; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Davies, MJ; Farnier, M; Gumbiner, B; Macdonell, G; Musliner, TA; Perevozskaya, I; Tribble, DL | 1 |
| Farnier, M; Kush, D; Mitchel, YB; Perevozskaya, I; Taggart, WV | 1 |
| Robinson, JG | 1 |
| Ansquer, JC; Bekaert, I; Guy, M; Hanefeld, M; Simon, A | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Visseren, FL; Westerink, J | 1 |
| Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A | 1 |
| Day, A; Kumar, SS; LaHaye, SA; Lahey, KA | 1 |
| Dunn, FL | 1 |
| Phillips, W; Schaefer, S | 1 |
| Drakopoulou, M; Skoumas, I; Stefanadis, C; Toutouzas, K | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Inui, K; Iwayanagi, Y; Suzuki, H; Takada, T; Terada, T; Tomura, F; Yamanashi, Y | 1 |
| Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Cao, G; Konrad, RJ; Troutt, JS | 1 |
| Kishimoto, M; Noda, M; Okamoto, M; Osame, K; Sugiyama, T; Takarabe, D | 1 |
| Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 1 |
| Bandgar, TR; Faruqui, AA | 1 |
| Prasad, V; Vandross, A | 1 |
| Hellerstein, M; Turner, S | 1 |
| Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM | 1 |
| Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L | 1 |
| Brunet, A; Cannon, CP; DiCioccio, AT; Hanotin, C; Paehler, T; Pinquier, JL; Poitiers, F; Rey, J; Sasiela, WJ; Surks, HK | 1 |
| Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S | 1 |
| Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF | 1 |
| Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE | 1 |
| Arimura, A; Arimura, H; Deguchi, T; Hashiguchi, H; Kikuti, A; Kurano, M; Nishio, Y; Shinnakasu, A; Yamamoto, K | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Cao, JT; Chen, K; Fan, YQ; Gao, L; Wang, CQ; Wang, Y; Xie, YS; Xu, ZJ; Yin, ZF; Zhang, HL | 1 |
| Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E | 1 |
| Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S | 1 |
| Banach, M; Katsiki, N; Mikhailidis, DP | 1 |
| Chmiel, K; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Paluch, M | 1 |
| Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
16 review(s) available for ezetimibe and fenofibrate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size | 2003 |
Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
Topics: Azetidines; Drug Combinations; Drug Synergism; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2007 |
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias | 2007 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2006 |
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.
Topics: Allylamine; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors | 2008 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke | 2008 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Advancing therapy for hypercholesterolemia.
Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Niacin | 2010 |
Reverse cholesterol transport fluxes.
Topics: Arthritis, Rheumatoid; Azetidines; Biological Transport; Cholesterol; Ezetimibe; Fenofibrate; Humans; Hypoalphalipoproteinemias | 2014 |
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL | 2014 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides | 2018 |
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Renal Insufficiency, Chronic | 2019 |
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins | 2023 |
20 trial(s) available for ezetimibe and fenofibrate
| Article | Year |
|---|---|
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
Topics: Adult; Azetidines; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pilot Projects; Single-Blind Method; Treatment Outcome | 2004 |
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2005 |
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2006 |
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Topics: Adult; Azetidines; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Glucuronides; Humans; Hypolipidemic Agents; Male; Middle Aged | 2006 |
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Particle Size; Triglycerides | 2008 |
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Simvastatin | 2008 |
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter,
Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2010 |
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Triglycerides | 2011 |
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2014 |
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Young Adult | 2016 |
Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult | 2017 |
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Combined Modality Therapy; Diet Therapy; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic Agents; Injection Site Reaction; Male; Middle Aged; PCSK9 Inhibitors; Treatment Outcome | 2016 |
20 other study(ies) available for ezetimibe and fenofibrate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Management of mixed hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2005 |
Ezetimibe coadministered with fenofibrate: some safety questions.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Drug Combinations; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias | 2005 |
[Ezetimibe with statins].
Topics: Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2006 |
Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Creatinine; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fenofibrate; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Male; Middle Aged | 2006 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hypolipidemic Agents; Indoles; Metabolic Syndrome; Simvastatin | 2010 |
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Middle Aged; Niacin | 2010 |
Human NPC1L1 expression is positively regulated by PPARα.
Topics: Azetidines; Cholesterol; Electrophoretic Mobility Shift Assay; Enterocytes; Ezetimibe; Fenofibrate; Gene Expression Regulation; Hep G2 Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Membrane Proteins; Membrane Transport Proteins; Niemann-Pick Diseases; PPAR alpha; PPAR gamma; Protein Binding; Response Elements | 2011 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2011 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles | 2011 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides | 2017 |
The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prognosis | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Model design for screening effective Antihyperlipidemic drugs using zebrafish system.
Topics: Animals; Atorvastatin; Biomarkers; Cholesterol; Diet, High-Fat; Disease Models, Animal; Drug Discovery; Ezetimibe; Fenofibrate; High-Throughput Screening Assays; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Triglycerides; Zebrafish | 2017 |
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Simvastatin | 2021 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |